Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Fuji raises FY3/27 forecast, sees orders at JPY 256 billion and operating profit at JPY 60 billion

Fuji raises FY3/27 forecast, sees orders at JPY 256 billion and operating profit at JPY 60 billion

ReutersReuters2026/08/03 06:37
  • Fuji lifted its FY3/27 outlook, forecasting orders of JPY 256,000 million, up 23.4% year on year, up 21.3% versus prior guidance.
  • Net sales forecast raised to JPY 244,000 million, up 35.1% year on year, up 15.6% versus the previous forecast.
  • Operating profit outlook increased to JPY 60,000 million, up 104.9% year on year, up 37.6% versus prior guidance.
  • Guidance followed Q1 results with orders of JPY 85,784 million, net sales of JPY 60,597 million, operating profit of JPY 15,212 million.
  • Outlook assumes sustained AI-related demand, with supply-chain capacity to be strengthened to meet rising mounter market demand.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fuji Corporation published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage